Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
During the past 3 years, the average EBITDA Per Share Growth Rate was 20.60% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
During the past 13 years, the highest 3-Year average EBITDA Per Share Growth Rate of Allergy Therapeutics was 44.20% per year. The lowest was -130.80% per year. And the median was -1.20% per year.
EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.
Allergy Therapeutics 3-Year EBITDA Growth Rate Related Terms
AGYTF vs ZTS, UTHR: 3-Year EBITDA Growth Rate Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Allergy Therapeutics's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Allergy Therapeutics 3-Year EBITDA Growth Rate vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Allergy Therapeutics's 3-Year EBITDA Growth Rate distribution charts can be found below:
* The bar in red indicates where Allergy Therapeutics's 3-Year EBITDA Growth Rate falls into.
This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
What does a 3-Year EBITDA Growth Rate of 20.60% mean?
Allergy Therapeutics (AGYTF) has a 3-Year EBITDA Growth Rate of 20.60% as of Dec. 2025. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Allergy Therapeutics and its competitors. According to the industry distribution chart, Allergy Therapeutics ranks #251 out of 805 companies in the Drug Manufacturers industry, placing it in the top 31.2%.
Is Allergy Therapeutics' 3-Year EBITDA Growth Rate too high?
Allergy Therapeutics' current 3-Year EBITDA Growth Rate is 20.60%. The Drug Manufacturers industry median 3-Year EBITDA Growth Rate is 8.90. Allergy Therapeutics' value of 20.60% is 131.5% above this industry median. Based on the distribution chart, Allergy Therapeutics ranks #251 out of 805 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Allergy Therapeutics has a GF Score™ of 24/100, reflecting its overall financial health beyond just this single metric.
How does Allergy Therapeutics' 3-Year EBITDA Growth Rate compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Allergy Therapeutics ranks #251 out of 805 companies for 3-Year EBITDA Growth Rate. This puts Allergy Therapeutics in the upper half of its industry. The industry median 3-Year EBITDA Growth Rate is 8.90. Allergy Therapeutics' value of 20.60% is 131.5% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EBITDA Growth Rate for a Drug Manufacturers company?
The median 3-Year EBITDA Growth Rate among Drug Manufacturers companies is 8.90, based on 805 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EBITDA Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Allergy Therapeutics's current 3-Year EBITDA Growth Rate of 20.60% is 131.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EBITDA Growth Rate mean?
A high 3-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Allergy Therapeutics and its competitors. For the Drug Manufacturers industry, the median 3-Year EBITDA Growth Rate is 8.90 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Allergy Therapeutics's current 3-Year EBITDA Growth Rate is 20.60%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Allergy Therapeutics stock overvalued right now?
Allergy Therapeutics (AGYTF) has a current 3-Year EBITDA Growth Rate of 20.60%. The stock's GF Value™ is $0.09, compared to a current price of $0.15 — trading 66.7% above its estimated fair value. The current 3-Year EBITDA Growth Rate is 20.60% and 131.5% above the Drug Manufacturers industry median of 8.90. Allergy Therapeutics' overall GF Score™ is 24/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EBITDA Growth Rate calculated?
3-Year EBITDA Growth Rate is calculated from a company's financial statements. For Allergy Therapeutics (AGYTF), the current 3-Year EBITDA Growth Rate is 20.60% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Allergy Therapeutics (AGYTF) Overvalued in 2026?
Based on GuruFocus' analysis, Allergy Therapeutics stock appears to be overvalued.
The current stock price of $0.15 is trading 66.7% above its estimated GF Value™ of $0.09.
Key valuation signals for AGYTF:
3-Year EBITDA Growth Rate: 20.60%
GF Value™: $0.09 vs. price of $0.15 (66.7% above fair value)
Industry Position: 131.5% above the Drug Manufacturers median (#251 of 805)
No single metric tells the full story. See the AGYTF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Allergy Therapeutics plc is an international biotechnology group focused on the diagnosis and treatment of allergic disorders through immunotherapies that target the underlying cause of disease. Its portfolio includes Pollinex, Pollinex Quattro, Acarovac, Tyrosine S/TU, Venomil, Oralvac and other allergy immunotherapy products, supported by R&D programmes such as Grass MATA MPL and VLP Peanut. The Group operates in a single class of business, being the manufacture and sale of allergy-related medicines, and maintains centralised manufacturing and research and development capabilities in the UK. Its geographical presence covers Central Europe (Germany, Austria, Switzerland and the Netherlands), Southern Europe (Spain and Italy) and the Rest of the World (including the UK).
24GF Score
Get the complete analysis for AGYTF
3-Year EBITDA Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
AGYTF has been successfully added to your 
